This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kisselev, P. Articles by Schwarz, D. Search for Related Content PubMed PubMed Citation Articles by Kisselev, P. Articles by Schwarz, D.

Association of CYP1A1 Polymorphisms with Differential Metabolic Activation of 17ß-Estradiol and Estrone

¹ Institute of Clinical Pharmacology, Charité–Campus Mitte, University Medicine Berlin, Humboldt University of Berlin and ² Max Delbrueck Center for Molecular Medicine, Berlin, Germany; and ³ Institute of Bioorganic Chemistry, Academy of Sciences of Belarus, Minsk, Belarus

Requests for reprints: Dieter Schwarz, Institute of Clinical Pharmacology, Charité–Campus Mitte, University Medicine Berlin, Schumannstr. 20-21, 10117 Berlin, Germany. Phone: 49-30-450-525-004; Fax: 49-30-450-525-933; E-mail: dieter.schwarz{at}charite.de.

Several epidemiologic studies associate certain CYP1A1 genotypes, alone or in combination, with an increased risk of estrogen-related cancers. To answer the question of whether genotype-dependent activation of estrogens by CYP1A1 could be the underlying mechanism, we studied the hydroxylation activity of the most common allelic variants of human CYP1A1 towards both endogenously occurring estrogens, 17ß-estradiol (E2) and estrone (E1). We expressed and purified CYP1A1.1 (wild-type), CYP1A1.2 (Ile⁴⁶²Val), and CYP1A1.4 (Thr⁴⁶¹Asn) and did enzymatic assays of NADPH-dependent estrogen hydroxylation in reconstituted CYP1A1 systems. All CYP1A1 variants catalyzed the formation of 2-, 4-, 6-, and 15-hydroxylated estrogen metabolites from E2 and E1, yet with varying catalytic efficiency and distinct regiospecificity. Whereas the variant CYP1A1.2 (Ile⁴⁶²Val) had a significant higher catalytic activity for all hydroxylation sites and both substrates, it was most pronounced for 2-hydroxylation. Catalytic efficiencies for the formation of the major metabolites, 2-OH-E2 and 2-OH-E1, by CYP1A1.2 were 5.7- and 12-fold higher, respectively, compared with the wild-type enzyme. The catalytic efficiencies for hydroxylations catalyzed by CYP1A1.4 were roughly comparable with those of the wild-type enzyme. Enzyme kinetics showed that the superior activity of CYP1A1.2 (Ile⁴⁶²Val) is mainly caused by a higher V_max, whereas K_m values of all variants were similar. The data suggest that risk of estrogen-induced cancers and cardiovascular diseases might be—at least partially—determined by the CYP1A1 genotype.

Key Words: CYP1A1 • pharmacogenetics • estrogen • metabolic activation • polymorphism

This article has been cited by other articles:

				B. Diergaarde, J. D. Potter, E. R. Jupe, S. Manjeshwar, C. D. Shimasaki, T. W. Pugh, D. C. DeFreese, B. A. Gramling, I. Evans, and E. White Polymorphisms in Genes Involved in Sex Hormone Metabolism, Estrogen Plus Progestin Hormone Therapy Use, and Risk of Postmenopausal Breast Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1751 - 1759. [Abstract] [Full Text] [PDF]

				S. K. Holt, M. A. Rossing, K. E. Malone, S. M. Schwartz, N. S. Weiss, and C. Chen Ovarian Cancer Risk and Polymorphisms Involved in Estrogen Catabolism Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 481 - 489. [Abstract] [Full Text] [PDF]

				S. I. Berndt, N. Chatterjee, W.-Y. Huang, S. J. Chanock, R. Welch, E. D. Crawford, and R. B. Hayes Variant in Sex Hormone-Binding Globulin Gene and the Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 165 - 168. [Abstract] [Full Text] [PDF]

				A. E. Cribb, M. J. Knight, D. Dryer, J. Guernsey, K. Hender, M. Tesch, and T. M. Saleh Role of polymorphic human cytochrome p450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 551 - 558. [Abstract] [Full Text] [PDF]